These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35469217)

  • 21. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
    Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
    BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering.
    Tang M; Gao C; Goutman SA; Kalinin A; Mukherjee B; Guan Y; Dinov ID
    Neuroinformatics; 2019 Jul; 17(3):407-421. PubMed ID: 30460455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Research on Traditional Chinese Medicine compounds and their preparations for Amyotrophic Lateral Sclerosis.
    Zhu J; Shen L; Lin X; Hong Y; Feng Y
    Biomed Pharmacother; 2017 Dec; 96():854-864. PubMed ID: 29078263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
    Hu N; Shen D; Yang X; Cui L; Liu M
    Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the Measurement Properties of the Self-Administered Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): A Rasch Analysis.
    Mehdipour A; Teshler L; Dal Bello-Haas V; Richardson J; Beauchamp M; Turnbull J; Chum M; Johnston W; O'Connell C; Luth W; Kuspinar A
    Phys Ther; 2023 Nov; 103(11):. PubMed ID: 37581600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.
    Karanevich AG; Statland JM; Gajewski BJ; He J
    BMC Med Res Methodol; 2018 Feb; 18(1):19. PubMed ID: 29409450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure.
    Varma A; Weinstein J; Seabury J; Rosero S; Zizzi C; Alexandrou D; Wagner E; Dilek N; Heatwole J; Wuu J; Caress J; Bedlack R; Granit V; Statland J; Mehta P; Benatar M; Kaat A; Heatwole C
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Aug; 24(5-6):514-522. PubMed ID: 37190795
    [No Abstract]   [Full Text] [Related]  

  • 31. Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.
    Wei Q; Zheng Z; Guo X; Ou R; Chen X; Huang R; Yang J; Shang H
    Neurol Sci; 2016 Apr; 37(4):557-63. PubMed ID: 26758858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis.
    De Marchi F; Berry JD; Chan J; Caldwell S; Ellrodt A; Scalia J; Burke K; Fang T; Clark Sisodia R; Schwamm LH; Moura LMVR; Paganoni S
    J Neurol; 2020 Jun; 267(6):1754-1759. PubMed ID: 32125520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale in Poland and its reliability in conditions of the medical experiment.
    Maksymowicz S; Kukołowicz P; Siwek T; Rakowska A
    Neurol Sci; 2021 Mar; 42(3):943-949. PubMed ID: 32676760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.
    Cedarbaum JM; Stambler N
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S1-9. PubMed ID: 9419047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dyspnea in Amyotrophic Lateral Sclerosis: Rasch-Based Development and Validation of a Patient-Reported Outcome (DALS-15).
    Vogt S; Petri S; Dengler R; Heinze HJ; Vielhaber S
    J Pain Symptom Manage; 2018 Nov; 56(5):736-745.e2. PubMed ID: 30145215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
    Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of Gastrointestinal Symptoms, Severity of Dysphagia, and Their Correlation with Severity of Amyotrophic Lateral Sclerosis in a Mexican Cohort.
    Parra-Cantu C; Zaldivar-Ruenes A; Martinez-Vazquez M; Martinez HR
    Neurodegener Dis; 2021; 21(1-2):42-47. PubMed ID: 34139704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X
    Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
    Chapin JL; Gray LT; Vasilopoulos T; Anderson A; DiBiase L; York JD; Robison R; Wymer J; Plowman EK
    PLoS One; 2020; 15(8):e0236804. PubMed ID: 32790801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.